Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotechnology 2004—the numbers

Nature Biotechnology volume 23, pages 663–671 (2005)Cite this article

Last year, public biotech companies made gains in revenues and profits, but with stock markets lackluster and regulatory issues looming, future growth remains uncertain.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Historical trends in biotech IPOs.
Figure 2: Global public and private biotech industry financing.
Figure 3: Public biotech companies by geographical location.
Figure 4: Public biotech companies by sector of application.
Figure 5: Public biotech revenue, R&D spending and profit by market cap.

Author information

Author notes

  1. Data retrieval for this article was by Riku Lähteenmäki and Stacy Lawrence, freelance writers working in Turku, Finland and San Francisco, respectively. Stacy Lawrence provided the analysis, with consultation provided by John Hodgson, Critical I, Banbury, OX16 9PA, UK.

Authors
  1. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacy Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Public biotechnology 2003—the numbers

Web links

CriticalI

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lähteenmäki, R., Lawrence, S. Public biotechnology 2004—the numbers. Nat Biotechnol 23, 663–671 (2005). https://doi.org/10.1038/nbt0605-663

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0605-663

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing